Scarica l'app Stockscreener
16.25
2.14%
0.34
Dopo l'orario di chiusura:
16.29
0.04
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
Can MoonLake Immunotherapeutics keep up with sector leadersMarket Activity Recap & AI Based Buy/Sell Signal Reports - mfd.ru
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
(MLTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Risk Analysis: What is the implied volatility of JWEL2025 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.6%Here's What Happened - MarketBeat
Zacks Research Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - MSN
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
MoonLake shares surge after FDA outlines approval route for HS therapy - MSN
Forecast Cut: Can TRINI deliver alphaRate Cut & Risk Managed Investment Entry Signals - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials - simplywall.st
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Moonlake surges as no additional studies are required for lead drug - MSN
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MoonLake Immunotherapeutics(MLTX.US) to Sell Rating, Raises Target Price to $10 - 富途资讯
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns - Investing.com Canada
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs - TipRanks
MACD Signal: Is MoonLake Immunotherapeutics stock suitable for long term investingTrade Risk Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Stop Loss: Is IGMS benefiting from interest rate changes2025 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Exit Recap: Will MoonLake Immunotherapeutics stock continue upward momentumOil Prices & Safe Capital Growth Stock Tips - moha.gov.vn
Death Cross: How is MoonLake Immunotherapeutics managing supply chain issues2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Buyback Watch: What is the Moat Score of MoonLake ImmunotherapeuticsMarket Sentiment Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
Guidance Update: Why MoonLake Immunotherapeutics stock could rally in 2025Take Profit & AI Powered Market Trend Analysis - Bộ Nội Vụ
Published on: 2026-01-13 06:01:31 - Улправда
(MLTX) Risk Channels and Responsive Allocation - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.3%Time to Sell? - MarketBeat
MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations - MSN
Why MoonLake Immunotherapeutics (MLTX) Is Up 54.7% After FDA Opens Path to HS BLA Filing - simplywall.st
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
BTIG Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途资讯
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $45 - 富途牛牛
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 9.6%Time to Buy? - MarketBeat
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - BioPharma Dive
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at HC Wainwright - MarketBeat
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
BTIG Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com Nigeria
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street By Investing.com - Investing.com South Africa
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):